Bicara and Merus Compete in HNSCC Drug Development RaceASCOBicara and Merus are advancing competing therapies for head and neck cancer (HNSCC). While Merus shows strong early OS data, Bicara focuses on long-term outcomes, especially in HPV-negative patients, with a pivotal trial underway.
